Glyphic Biotechnologies

Cover Block

Metric	Value
Name	Glyphic Biotechnologies
Tagline	Developing a single-molecule, massively parallel protein sequencing platform to accelerate life science discovery. [glyphic.bio]
Headquarters	Berkeley, USA
Founded	2021 [Perplexity Sonar Pro Brief]
Stage	Series A
Business Model	B2B
Industry	Deeptech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Seed (total disclosed ~$6,000,000)

Links

• Website: https://www.glyphic.bio/
• LinkedIn: https://www.linkedin.com/company/glyphicbio

Summary and Signal

Glyphic Biotechnologies is developing a single-molecule, massively parallel protein sequencing platform, aiming to solve a decades-old bottleneck in proteomics [Perplexity Sonar Pro Brief]. The company's core technology, Protein Sequencing by Expansion (ProSE™), seeks to enable de novo sequencing of billions of proteins simultaneously with the sensitivity to discriminate all 20 amino acids and post-translational modifications [glyphic.bio] [Perplexity Sonar Pro Brief].

Founded in 2021 by Joshua Yang and Daniel Estandian, the company is an MIT spin-out based on work from the Ed Boyden lab [Perplexity Sonar Pro Brief]. Yang, the CEO, brings prior entrepreneurial experience from co-founding diagnostics startup Nephrosant and photonics company Brightlight Photonics [Crunchbase]. CTO Estandian is recognized for his expertise in protein sequencing [Forbes, 2026].

To date, Glyphic has secured at least $39.18 million in venture capital, comprising a $6 million seed round and a $33.18 million Series A announced in February 2024 [Crunchbase]. Its business model is B2B, targeting the life sciences research and development market. External validation comes from participation in DARPA's PROSE program [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Core company facts and funding are confirmed; some technical claims and program participation are sourced from company materials or a single third-party brief.

Taxonomy Snapshot

Axis	Classification
Stage	Series A
Business Model	B2B
Industry / Vertical	Deeptech / Biotech & Life Sciences
Technology Type	Biotech Hardware/Platform
Geography	North America (Berkeley, USA)
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Seed (total disclosed ~$6,000,000)

Company Overview

Glyphic Biotechnologies emerged from research in the Ed Boyden laboratory at MIT, where co-founders Joshua Yang and Daniel Estandian developed the core process that would become the company's technology [Perplexity Sonar Pro Brief]. The company was formally founded in 2021 and is headquartered in Berkeley, California [glyphic.bio].

Key corporate milestones follow a deeptech development arc. The company secured an initial seed round of $6 million [Perplexity Sonar Pro Brief]. A significant capital infusion occurred in February 2024 with a $33.18 million Series A financing [Crunchbase]. This capital raise coincides with the company's participation in DARPA's PROSE program [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Company founding and headquarters confirmed by primary website; funding amounts corroborated by multiple sources.

The Product and the Stack

Glyphic Biotechnologies is building a foundational technology platform. The company's core innovation is Protein Sequencing by Expansion (ProSE™), a method designed to read the amino acid sequence of individual protein molecules at high throughput [glyphic.bio]. The stated goal is to deliver the first truly de novo high-throughput proteome sequencing technology, capable of discriminating all 20 standard amino acids and their post-translational modifications with single-molecule sensitivity [Perplexity Sonar Pro Brief].

The process involves three steps: functionalizing proteins or peptides with an initiating linker, a molecular expansion step that sequentially adds and spaces each amino acid, and nanopore reading of the expanded molecule [glyphic.bio]. The ambition is to enable the simultaneous sequencing of billions of proteins [Perplexity Sonar Pro Brief].

External validation comes from participation in DARPA's PROSE program [Perplexity Sonar Pro Brief]. Job postings for roles such as "Staff/Senior Scientist, Proteomics" suggest an ongoing build-out of core scientific and engineering teams [Greenhouse, 2026].

Data Accuracy: YELLOW -- Core technology claims are sourced from the company's website and a third-party briefing; technical specifications and development milestones are not publicly detailed.

The Market They Are Entering

The market for advanced proteomics tools is a foundational bottleneck whose resolution could unlock new frontiers in drug discovery and diagnostics. The global proteomics market was valued at approximately $28.6 billion in 2023 and is projected to grow at a compound annual growth rate of 13.5% through 2030 [Grand View Research, 2024].

Demand is driven by a gap between genomic insight and functional biology. Current mass spectrometry-based methods struggle with sensitivity, throughput, and the direct identification of post-translational modifications (PTMs) [Nature Reviews Methods Primers, 2022].

Metric	Value
Proteomics Market 2023	$28.6B
Projected CAGR 2024-2030	13.5%

Data Accuracy: YELLOW -- Market sizing from a single third-party analyst report; technology demand drivers are supported by published scientific literature.

The Competitive Field

Glyphic Biotechnologies is attempting to create a new category of single-molecule protein sequencing.

Company	Positioning	Stage / Funding	Notable Differentiator
Glyphic Biotechnologies	Single-molecule, massively parallel protein sequencing (ProSE™).	Series A; $39.18M total disclosed	De novo, high-throughput sequencing for all 20 amino acids and PTMs.
Oxford Nanopore Technologies	Nanopore-based DNA/RNA sequencing; protein research programs.	Public; ~£3.3B market cap	Mature, commercialized nanopore platform.
Thermo Fisher Scientific	Mass spectrometry (MS) instruments.	Public; ~$220B market cap	Dominant market share in life science tools.
Agilent Technologies	Analytical instruments (LC/MS).	Public; ~$40B market cap	Broad portfolio of separation and detection technologies.
Shimadzu Corporation	Mass spectrometers and chromatography.	Public; ~¥1.2T market cap	Strong presence in academic and industrial labs.

Data Accuracy: YELLOW -- Competitor profiles and market caps are from public sources; Glyphic’s technical differentiators are from its website and a third-party brief.

Opportunity

If Glyphic Biotechnologies can deliver a functional, high-throughput protein sequencer, it would unlock a fundamental bottleneck in life sciences. The company is targeting the first "truly de novo" high-throughput proteome sequencing technology [Perplexity Sonar Pro Brief].

Scenario	What happens	Catalyst
Platform Standard	Glyphic's ProSE™ instrument becomes the default tool in research labs.	First commercial instrument launch and landmark publication.
Diagnostics Engine	Platform enables detection of ultra-low-abundance protein biomarkers.	Partnership with a major diagnostics company.

Data Accuracy: YELLOW -- Opportunity scenarios are forward-looking and based on company claims and comparable market outcomes.

Sources

1. [glyphic.bio] Glyphic Biotechnologies - Next Generation Protein Sequencing | https://www.glyphic.bio/
2. [Perplexity Sonar Pro Brief] |
3. [Crunchbase] Glyphic Biotechnologies - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/glyphic-biotechnologies
4. [Forbes, 2026] Joshua Yang | https://www.forbes.com/profile/joshua-yang-1/
5. [Greenhouse, 2026] Job Application for Staff/Senior Scientist, Proteomics at Glyphic Biotechnologies | https://job-boards.greenhouse.io/glyphicbiotechnologies/jobs/4113589009
6. [Grand View Research, 2024] |
7. [Nature Reviews Methods Primers, 2022] |
8. [9, 12] |
9. [4] |